ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns

ANI PHARMACEUTICALS INC

Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.
Gosebruch is CEO of Lakefront Biotherapeutics (formerly Galapagos) since May 2025; ex-CEO of Neumora, ex-EVP Chief Strategy Officer at AbbVie.
Gosebruch receives initial restricted stock award with grant date fair value $525,000, vesting in 3 equal annual installments.
Samy Shanmugam resigned as director effective Aug 23, 2026; remains Head of R&D and COO of New Jersey Operations.
Gosebruch brings 30+ years experience; expected to strengthen business development and capital allocation as ANI accelerates Rare Disease transformation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.